January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
10 citations
,
October 2019 in “Australasian Journal of Dermatology” Secukinumab effectively treated a difficult case of folliculitis decalvans.
April 2021 in “Journal of Investigative Dermatology” The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
1 citations
,
July 2021 in “Acta dermatovenerologica Croatica” Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.
3 citations
,
January 2011 in “American Journal of Hematology” Immunochemotherapy successfully treated neutropenia in a patient with Waldenström's macroglobulinemia.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
August 2023 in “Dermatology and Therapy” Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.
1 citations
,
April 2013 in “PubMed”
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
1 citations
,
January 2022 in “Oxidative Medicine and Cellular Longevity” Hair follicle stem cells can help treat ulcerative colitis in mice by releasing beneficial exosomes.
1 citations
,
May 2024 in “Skin Appendage Disorders” Hair regrowth was achieved using 5-Fluorouracil and Bleomycin for scalp atrophy caused by corticosteroids.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
28 citations
,
March 2018 in “Archives of Dermatological Research” 75 citations
,
June 2005 in “Archives of Dermatology” Etanercept may not prevent alopecia areata from coming back.
14 citations
,
February 2023 in “Frontiers in immunology” Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
33 citations
,
June 2021 in “Dermatologic Therapy” COVID-19 vaccines can trigger autoimmune flares but are still beneficial for patients with autoimmune conditions.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
12 citations
,
May 2018 in “JAAD Case Reports” A man's gray hair got darker and thicker after using a psoriasis drug.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
3 citations
,
July 2018 in “European Journal of Dermatology” An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.
November 2023 in “Frontiers in pharmacology” Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
1 citations
,
March 2022 in “JAAD case reports” Methotrexate injection site reactions are rare but can be managed by changing injection sites and using topical treatments.
8 citations
,
December 2018 in “Journal of Dermatological Treatment” The PRP-like cosmetic with biomimetic peptides is potentially effective and safe for treating alopecia areata.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
10 citations
,
January 2018 in “International Journal of Trichology” Mesalazine may help treat extensive alopecia areata effectively.
March 2026 in “Journal of Translational Autoimmunity” This study investigates the mechanisms by which ruxolitinib, a JAK inhibitor, reverses alopecia areata (AA) in a C3H/HeJ mouse model. Over 98 days, ruxolitinib treatment led to significant hair regrowth by day 85, reduced inflammatory cytokines, decreased T-cell infiltration, and lowered STAT phosphorylation. It also attenuated local oxidative stress and keratinocyte apoptosis without affecting autophagy or systemic oxidative markers. The study concludes that ruxolitinib's efficacy in treating AA is due to a triple mechanism: inhibition of the JAK-STAT pathway, reduction of local oxidative stress and apoptosis, and disruption of the inflammatory cycle, supporting the potential for targeted topical therapies.
20 citations
,
March 2017 in “Arthritis research & therapy” Social media can help compare the effectiveness and safety of new arthritis medications.
6 citations
,
June 1983 in “Cancer” A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.